SCHEDULE: Armistice Capital Updates Palisade Bio Stake

Armistice Capital and Steven Boyd report a 4.99% passive ownership stake in Palisade Bio, Inc. common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively the Reporting Persons, have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Palisade Bio, Inc.
• As of the event date of June 30, 2025, the Reporting Persons beneficially own an aggregate of 478,945 shares of Palisade Bio, Inc. Common Stock.
• This ownership represents 4.99% of the total class of securities.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, inherently neutral in sentiment regarding the company's performance or prospects.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's operations or financial performance.

Industry Context

This filing is a standard disclosure of an institutional investor's passive ownership stake in a publicly traded company, common practice within the financial industry for transparency regarding significant holdings.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming no intent to influence control.

Key Dates

Keywords

Palisade Bio, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management